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ABSTRACT
Until today, the susceptibility of human immunodeficiency virus type 2 (HIV-2) to protease and nucleosidic
reverse-transcriptase inhibitors (PI and NRTI, respectively) has not been clearly documented. In this report
we studied HIV-2 proviral sequences (n  30) from drug-naive patients. Our results revealed that several
amino acid positions in the protease and reverse transcriptase coding sequence harbored residues that have
been associated with drug resistance in HIV-1-infected patients. In particular, the M46I substitution in the
protease was detected in 90% of the sequences analyzed, which, together with the other substitutions identi-
fied, may indicate a reduced susceptibility of HIV-2-infected drug-naive patients to PI. Furthermore, inter-
pretation of genotypic data with four available algorithms, developed for interpretation of HIV-1 sequence
data, suggested nonoverlapping profiles of drug resistance.
THE IMPRESSIVE DEGREE OF GENETIC VARIABILITY displayedby the human immunodeficiency virus (HIV) accounts for
the continuous generation of molecular variants, and endows
this infectious agent with the capacity to rapidly overcome en-
vironmental selective pressures, such as those imposed by the
host immune system or antiretroviral (ARV) therapy.1
Both HIV-1 and HIV-2 cause AIDS, but while HIV-1 has
spread all over the world, HIV-2 infections remain, somehow,
restricted to West Africa. A noteworthy exception is Portugal,
where HIV-2 still accounts for approximately 4% of the total
number of AIDS cases (information available at http://www.
insarj.pt).
Over the past decade, the implementation of highly effective
combination therapy with ARV drugs has greatly reduced the
morbidity and mortality among HIV-infected individuals. The
main therapeutic drugs used to restrain viral multiplication tar-
get two essential viral enzymes, both encoded by the pol gene:
the protease (PR) and the reverse transcriptase (RT). However,
in those cases in which only partial suppression of viral repli-
cation is achieved, emergence and selection of drug-resistant
viruses, which tend to accumulate over time, seems to be a com-
mon event.2
Numerous studies focused on HIV drug resistance have cor-
related critical amino acid substitutions in Pol with resistance
to PR inhibitors (PI), nucleoside/nucleotide RT inhibitors
(NRTI), and non-NRTI (NNRTI).3,4 Most of the current knowl-
edge on HIV drug resistance is, however, based on data ob-
tained for HIV-1 subtype B. Comparatively less is known about
HIV-2, for which a commercially available method for quan-
tification of viral RNA in the plasma is still lacking, and large-
scale clinical trials using ARV drugs have yet to be conducted.
Despite the low sequence identity between the HIV-1 and
HIV-2 genomes, pol genes from these viruses share 50% iden-
tity in the PR and 60% in the RT sequences, and both enzymes
retain the same overall functionality.5–7 This finding led to the
suggestion that at least some of the drugs effective against HIV-
1 could also be useful to manage HIV-2 infections.8 Accord-
ingly, and despite the fact that knowledge about treatment of
HIV-2 patients is still limited (because few patients have been
treated and randomized trials are lacking), it usually follows the
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same overall strategy used for HIV-1. The clinical data indi-
cate that HIV-2 strains are sensitive to most PI and NRTI but,
like HIV-1 group O, are intrinsically resistant to the currently
used NNRTI.2,9 At present, there are no available validated as-
says to assess HIV-2 drug-resistance (either genotypic or phe-
notypic) in response to ARV drug selection.10 Moreover, to
date, a limited number of studies have reported the presence of
genotypic changes in the pol gene of HIV-2, which could be
drug resistance-associated mutations.9,11–14
In this report we describe the natural polymorphisms in
proviral pol genes, covering the PR and most of the RT from
drug-naive HIV-2-infected patients. Our analysis enrolled 15
individuals (10 males, 5 females), 22–67 years old (mean 40.1
years), all Africans (12 of whom originated from Guinea-Bis-
sau). The only self-reported mode of infection was heterosex-
ual contact, and only one of them indicated having been in-
fected in Portugal. Four of them evidenced symptoms of
advanced disease.
Peripheral blood mononuclear cells were separated by den-
sity centrifugation, and the preparation of whole cell lysates
was carried out as previously described.15 Partial HIV-2 pol
proviral sequences were amplified by nested polymerase chain
reaction (PCR) using primers Pol2Fo (5-GGAAAGAAGCC-
CCGCAACTTCCCCG-3, positions 1860 to 1884 in HIV-
2ROD) and Pol2Ro (5-CCTGGTGTATTTTATATGTCCACT-
GATTG-3, positions 3405–3433) in the first round, and Pol2Fi
(5-CAGAGGACTTGCTGCACCTCAATTCTCTC-3, posi-
tions 2072–2100) and Pol2Ri (5-TTTTGGATGTCATTGA-
CTGTCCATAYTTC-3, positions 3145–3173) in the second
round of amplification, using the puRe Taq Ready-to-go PCR
Beads (Amersham Biosciences) as recommended by the sup-
plier. The reaction conditions used in the first and second rounds
of PCR were the same. These included an initial denaturation
step at 94°C for 1 min, followed by 35 cycles of 94°C for 45
sec, 56°C for 30 sec (the hybridization temperature was low-
ered to 52°C in the first three cycles), and 72°C for 2 min, fol-
lowed by a final extension step of 5 min at 72°C.
PCR products were directly cloned into pGEM-T Easy
(Promega) and individual plasmid clones were purified and se-
quenced with fluorescent dye-coupled dideoxynucleotides with
an ABI PRISM 377 automated sequencer (Applied Biosys-
tems). DNA and predicted protein sequences were aligned with
ClustalW (available at http://www.ebi.ac.uk/clustalw) and man-
ually stripped for gaps. Neighbor-joining phylogenetic trees
were constructed from distance matrixes calculated by the
Kimura two-parameter method using the PHYLIP version 3.5
software package (through http://bioweb.pasteur.fr). Reference
sequences were obtained from the Los Alamos HIV sequence
database (available at http://hiv-web.lanl.gov/). HYPERMUT
and SNAP software (both available at http://hiv-web.lanl.gov/)
were used to detect G  A hypermutation and to calculate the
rate of nonsynonymous to synonymous substitutions (dN/dS),
respectively.
Altogether, we examined 30 nucleotide sequences that, by
phylogenetic inference analysis, were ascribed to HIV-2 group
A genomes (data not shown). When taken together with previ-
ous subtyping data, focused on the analysis of env or nef genes
amplified from the same DNA extracts,15,16 these results rein-
force a nonrecombinant nature for the viral genomes analyzed.
One of the examined sequences was found to be hypermutated
due to frequent G  A replacements, particularly associated
with GG and GA dinucleotides, resulting in the premature in-
troduction of translation stop codons within the Pol coding se-
quence by replacement of TGG by TAG (data not shown).
Analysis of the nucleotide sequences revealed genetic di-
versity values (percentage) of 8.7  2.4 and 9.3  2.6 (mean 
standard deviation) for the PR and RT coding segments, re-
spectively. In both regions we observed a predominance of syn-
onymous over nonsynonymous substitutions, clearly revealed
by the calculated dN/dS ratios (0.571 for the PR and 0.077 for
the RT coding sequences), and suggestive of negative (or pu-
rifying; dN/dS 1) selection.17
The DNA sequences obtained were inspected for natural
polymorphisms, and the amino acid variability at each site was
established by calculating the percentage of sequences show-
ing a specific residue at each position. We found that 42 (44.7%)
and 95 (38.1%) of the positions of the HIV-2 PR and RT, re-
spectively, varied spontaneously (Figs. 1 and 2). Among these,
positions 7, 10, 14, 40, 61, 65, 68, and 70 (in the PR, n  8)
and positions 4, 5, 10, 11, 28, 35, 43, 51, 83, 86, 126, 135, 162,
167, 173, 176, 180, and 228 (in the RT, n  18) were consid-
ered highly polymorphic, as 20% of the analyzed sequences
showed amino acid residues that differed from those most fre-
quently found. The HIV-2 PR and RT amino acid sequences
presented in this work are in agreement with the HIV-2 group
A consensus provided in the literature (see Figs. 1 and 2), with
the exception of position 167 in the RT, where the substitution
of valine by an isoleucine residue is suggested (Fig. 2).
The protease presents 3 noncontiguous functionally impor-
tant domains showing little amino acid variation (indicated in
Fig. 1 as active site, flap region, and substrate binding domain).
These correspond to domains of PR that are functionally im-
portant in HIV-1,18 and harbor similar amino acids at most po-
sitions,19 suggesting similar structural features for both en-
zymes. The PR active site and the substrate binding domain are
the two best conserved regions, while the flap region (positions
47–56) accommodates a slightly higher degree of variability.
Nevertheless, the patterns of natural polymorphisms between
HIV-1 and HIV-2 seem to be quite different. This is exempli-
fied by the fact that at least four of the highly polymorphic sites
in the HIV-2 sequences analyzed are well conserved sequences
in HIV-1 (positions 7, 14, 65, and 68). On the contrary, codon
63, which has been described as the most polymorphic position
in the HIV-1 PR, was absolutely conserved in all the sequences
analyzed, being occupied by a glutamate (E) residue, as previ-
ously reported.13
The proviral sequences obtained were inspected for detec-
tion of positions associated with HIV-1 drug resistance taking
into account the International AIDS Society4 (available at
http://www.iasusa.org/resistance_mutations/resistance.pdf) and
the HIVdb Drug Resistance algorithms (http://hivdb6.stan-
ford.edu). We compared the 21 positions associated with PI re-
sistance with the same ones in the HIV-2 sequences here de-
scribed and looked for the presence of major (30N, 33I/F, 46I/L,
48V, 50L/V, 82A/F/S/T/V, 84V, and 90M) and minor
(10I/V/F/R, 20I/L/M/R/T, 24I, 32I, 36I/L/V, 47A/V53L,
54A/L/M/S/T/V, 63P, 71T/V, 73A/C/S/T, 77I, and 88D/S) PI
resistance mutations. The data obtained are in agreement with
recent reports in the literature13,20 as they revealed that the
amino acid residues always (36I/V, 47V, 73A) or mostly found
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FIG. 2. Amino acid consensus derived from the multiple alignments of the deduced sequences for the HIV-2 RT. Amino acid
positions are indicated above residues along the RT sequence. The percentage of sequences containing a given amino acid at
each position is indicated as subscripts. The finger, palm, and thumb structural domains of the viral reverse transcriptase are in-
dicated by the vertical arrows. For comparison, the HIV-1 subtype B and HIV-2 group A consensus sequences [HIV-1(B) and
HIV-2(A), respectively] are also indicated.
FIG. 1. Amino acid consensus derived from the multiple alignments of the deduced sequences for the HIV-2 PR. Amino acid
positions are indicated above residues along the sequence. The percentage of sequences containing a given amino acid at each
position is indicated as subscripts. The protease conserved domains (active site, flap region substrate binding domain) are indi-
cated by the vertical arrows. For comparison the HIV-1 subtype B and HIV-2 group A consensus sequences [HIV-1(B) and HIV-
2(A), respectively] are also indicated. The five residues in boldface at the N-terminus of the protease sequences are encoded by
one of the PCR primers.
(10I/V, 32I, 46I, 71I/V) at seven positions in the HIV-2 se-
quences correspond to those conferring (46I) or contributing
(all other mutations) to PI resistance in HIV-1-infected patients.
Substitutions 32I, 47V 71V, and 73A were also rarely, or never,
seen in HIV-1 sequences but, on the contrary, 36I was very
common in HIV-1 from drug-naive patients. In particular, sub-
stitution M46I, rarely seen in global collections of HIV-1 se-
quences from drug-naive individuals, associated with resistance
to indinavir (IDV) or described as a minor mutation associated
with resistance to ritonavir (RTV), nelfinavir (NFV), ampre-
navir (APV), atazanavir (ATV), and lopinavir (LPV)/RTV
(http://hivdb.stanford.edu), was detected in 90% of the se-
quences reported here. The great majority of these harbored at
least six multiple PI resistance-associated mutations in patterns
featuring both the major M46I substitution and different minor
ones. The most commonly observed pattern was 10I/V, 32I,
36I, 46I, 47I, 71V, and 73A, suggesting, by the HIVdb algo-
rithm, intermediate (IR, with 10I) or high level (HLR, with 10V)
resistance to APV, IR resistance to ATV, IDV, LPV, NFV, and
RTV, and low level resistance (LLR) to SQV. Altogether, this
combination of mutations comprises 73% of the HIV-2 se-
quences analyzed, followed by 10I/V, 32I, 36I, 46I, 47I, and
73A (10%, indicating IR to all PI except SQV, for which LLR
is anticipated). It should, however, be mentioned that two of
the sequences analyzed (with the mutation pattern 10I, 32I, 36I,
46I, 47I, 71V, and 73A) are predicted to confer IR to all PI ex-
cept APV and NFV or ATV and NFV, for which HLR is ex-
pected, due to the N88D or N88S substitutions, respectively.
Altogether, these observations are in agreement with previous
results suggesting that HIV-2-infected drug-naive individuals
may show natural reduced susceptibility to PI.11,13,20
The same HIV-2 nucleotide sequences were also tentatively
analyzed using the Rega Institute (RegaInst, available at
www.kuleuven.ac.be/rega/cev/links/) and ANRS (Agence Na-
tional de Recherche sur le SIDA, available at www.hivfrench
resistance.org) algorithms, which have also been designed for
the interpretation of HIV-1 genotypic resistance data. In the first
case, 90% of the sequences indicate resistance to IDV and RTV.
However, in the second case, sequence analysis suggested over-
all resistance to IDV, possible resistance to NFV in the major-
ity of the sequences due to the widespread 36I, 46I combina-
tion.
In the RT we found that amino acid residues frequently/al-
ways localized at 11 positions (69N, 75I, 106I, 118I, 181I,
184L, 188L, 190A, 210N, 215S, and 219D), corresponded to
those contributing to ARV drug resistance in HIV-1 (Fig. 2).
Although some of these polymorphisms were characteristic of
HIV-2 RT, other regions such as those from positions 84–101,
143–161, and 229–240 were well conserved in both HIV-1 and
HIV-2 RT, and should probably be regarded in view of the de-
sign of new RT-inhibitory compounds. As expected, all the se-
quences analyzed evidenced at least two of the amino acid
residues 181I, 188L, and 190A, all of which are major muta-
tions associated with NNRTI resistance.
Our data also disclose the 69N/S polymorphism in all the se-
quences, which has been shown to confer reduced susceptibil-
ity to zidovudine (ZDV), didanoside (ddI), and stavudine (d4T).
This contrasts to what is observed for HIV-1, where these
residues are not usually encoded by RT sequences from drug-
naive patients.21 All the sequences analyzed evidenced the
T215S substitution (typical of HIV-2 genomes) that has been
described as a transitional mutation (to Y or F), conferring in-
creased risk of virologic failure of ZDV and d4T in HIV-1-in-
fected drug-naive adults starting therapy with these drugs.3
However, in HIV-2, it seems that mutations at positions 151
and 219, rather than 215, may be important for development of
ZDV resistance.12 While the first of these positions was ab-
solutely conserved, the second corresponds to a polymorphic
site in the sequences analyzed. Other infrequent mutations de-
tected, previously shown to have been selected in HIV-2 by
NRTI treatment,12,14 were 5V, 35R, and 223R. These were,
however, identified in our study as natural polymorphisms in
27%, 20%, and 10% of the sequences analyzed, respectively.
As reported by Colson and collaborators,14 the amino acid
residues 75I, 118I, and 219E, which potentially confer low-level
resistance to some NRTI in HIV-1, were frequently found.
Moreover, the 5V, 35R, and 223R mutations that emerge in
HIV-2 under NRTI-selective pressure were already found at a
low level (27%, 20%, and 10%, respectively) in the sequence
data reported.
Interpretation of the obtained HIV-2 genotypic data with the
HIVdb algorithm indicates potential IR or LLR to all the avail-
able NRTI, while the ANRS suggests potential resistance to
AZT and d4T (due to the presence of a T215S substitution in
all the sequences). Finally, the interpretation of the same geno-
typic data using the RegaInst algorithm gave somewhat less-re-
strictive genotypic resistance results suggesting resistance to
AZT (due to the combinations of the 69N and 219E substitu-
tions), and both ddC and ddI (due to the very frequent T69N
replacement).
Despite the documented similarities in the primary sequences
of the PR and RT of HIV-1 and HIV-2, some of the amino acid
substitutions causing, or contributing to, resistance to different
ARV drugs in HIV-1-infected patients seem to be natural poly-
morphisms in HIV-2. Conversely, certain natural, as well as
drug-selected polymorphisms typical of HIV-2 are not, or only
rarely, seen in HIV-1. Considering both situations, we still lack
consistent and accurate data on the impact of the different amino
acid substitutions on both viral fitness and level of drug resis-
tance in the course of an HIV-2 infection. Furthermore, analy-
sis of HIV-2 genotypic resistance with algorithms developed
for the interpretation of HIV-1 sequence data gives rise to di-
versity of drug-resistance profiles. In fact, different studies seem
to point toward the idea that the interpretation of HIV-2 geno-
typic resistance data should not be directly carried out using al-
gorithms developed for HIV-1. For example, a previous study
has suggested that the development of ZDV resistance in 
HIV-2 differs from that of HIV-1, and that resistance to PI ap-
pears to involve mutations in the HIV-2 PR not considered as
PI-resistance mutations in HIV-1.12 On the other hand,
Witvrouw et al.22 showed that despite the presence of the ma-
jor 46I PR mutation (as well as several other minor ones, e.g.,
10V, 32I, 36I, and 76V), HIV-2 ROD (group A) and ECHO
(group B) were sensitive to IDV, RTV, and SQV, while the
registered NFV and APV reduced sensitivity were not predicted
from the genotypic data. These observations seem to indicate
that the susceptibility of HIV-2 PR to ARV drugs is determined
by amino acid substitutions other than those contributing to
ARV drug resistance in HIV-1, and the same may hold true for
the HIV-2 RT.
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Like previous studies of genotypic resistance to ARV drugs
in HIV-2, ours is limited in the amount of the data provided
(number of sequences), but it documents several differences be-
tween HIV-2 group A and HIV-1 PR and RT. The identifica-
tion of mutations/polymorphisms in the pol gene of HIV-2 drug-
naive patients may be important for planning future studies that
will ascertain the pathways for development of PI/RT drug re-
sistance during ARV treatment. Indeed, as it is still rather un-
certain whether the amino acid substitutions associated with
drug resistance in HIV-1 and HIV-2 are the same, the algo-
rithms for the interpretation of HIV-2 genotypic resistance
should also take into account codons other than those strictly
associated with ARV drug resistance in HIV-1. The way nat-
ural polymorphisms of the HIV-2 PR and RT impact on the
phenotypic susceptibility of the different viral strains to ARV
drugs can be closely evaluated only by phenotypic drug sus-
ceptibility assays using HIV-2 sequences derived either directly
from patient material or created by in vitro mutagenesis. The
development of these phenotypic assays is, therefore, impera-
tive.
SEQUENCE DATA
The nucleotide sequences reported in this study have been
submitted to the EMBL/GenBank/DDBJ sequence databases
under the accession numbers AJ878426–AJ878455.
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